**Core Concept**
In HIV patients, characteristic fat distribution changes are attributed to the metabolic effects of antiretroviral therapy (ART) and the underlying disease process. These changes are part of a broader condition known as lipodystrophy syndrome, which affects the distribution and accumulation of body fat.

**Why the Correct Answer is Right**
Lipodystrophy syndrome in HIV patients often presents with peripheral lipoatrophy (loss of fat in the arms, legs, and face) accompanied by central lipohypertrophy (accumulation of fat around the abdominal and visceral organs). This phenomenon is thought to result from the mitochondrial toxicity of certain antiretroviral medications, which disrupt normal fat cell function and distribution.

**Why Each Wrong Option is Incorrect**
**Option A:** This is not a recognized fat distribution pattern in HIV patients.
**Option B:** While HIV patients may experience weight loss, it is not a characteristic fat distribution pattern associated with the condition.
**Option C:** This option is incorrect as it does not accurately describe the typical fat distribution changes seen in HIV patients.

**Clinical Pearl / High-Yield Fact**
HIV patients on certain antiretroviral medications are at increased risk of developing lipodystrophy syndrome, which can lead to significant changes in body composition and metabolic function. Clinicians should be aware of this potential side effect and monitor patients for signs of lipodystrophy.

**Correct Answer: C. Peripheral lipoatrophy with central lipohypertrophy.**